Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Koichi KidoShingo HatakeyamaKazuyuki NumakuraToshikazu TanakaMasaaki OikawaDaisuke NoroShogo HosogoeShintaro NaritaTakamitsu InoueTakahiro YoneyamaHiroyuki ItoShoji NishimuraYasuhiro HashimotoToshiaki KawaguchiTomonori HabuchiChikara OhyamaPublished in: International journal of clinical oncology (2020)
The oncological outcomes of patients receiving the first-line therapy of nivolumab plus ipilimumab in real-world practice were significantly improved in comparison with first-line TKIs therapy.